ALL

MONO-DUAL THERAPY

HAART

  p

Term (weeks)

38.1±2

38.5±2.4

37.8±1.7

<0.0001

Number of preterm infants (%)

42/292 (14.4%)

19/129 (14.7%)

23/163 (14.1%)

NS

Birth weight (g)

2925±569

2982±622

2872±525

<0.04

AZT dose per Kg per days  (mg)

7.7±0.7

7.8±0.7

7.7±0.7

NS

Length of post natal exposure (days)

35.7±8.3

38.6±7.8

33.3±7.8

<0.0001

AZT (%)

217/307 (71%)

86/136 (63%)

131/171 (77%)

NS

AZT+3TC*, ** (%)

54/307 (18%)

37/136 (27%)

17/171 (10%)

0.001

AZT + NVP*** (%)

36/307 (12%)

13/136 (10%)

23/171 (13%)

NS


*: 28 patients included in the ANRS075 study (see text);
**: 1 child received AZT+3TC+LPV;
***: 10 mother-child pairs included in the pACTG316-ANRS083 study (nevirapine
arm; see text)
Table 6: Newborns’ characteristics.